Stocksigma LogoStocksigma Logo

Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil

Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., launched RYALTRIS Nasal Spray in Brazil on 11th Sep'26

Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil

Glenmark Pharmaceuticals Ltd · Press Release · 11 Sept 2026, 2:20 pm

Glenmark Expands Respiratory Footprint with RYALTRIS Launch in Brazil Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., launched RYALTRIS Nasal Spray in Brazil on 11th Sep'26. Following ANVISA regulatory approval, it becomes Brazil's first olopatadine-containing intranasal combination therapy, treating moderate to severe allergic rhinitis in patients aged 12 and older. The launch targets a market where allergic rhinitis affects 20–30% of the population (40–60 million people). RYALTRIS, Glenmark's flagship globally commercialized branded innovative product, is currently approved in 57 markets worldwide, including the US, EU, UK, and China.

Original exchange filing (PDF)

More announcements from Glenmark Pharmaceuticals Ltd

All Glenmark Pharmaceuticals Ltd announcements